Clinician HPV vaccine recommendations in teens vary widely by US region, data suggest
News briefToday at 3:48 p.m.
Mary Van Beusekom, MS
Topics
Human Papillomavirus (HPV)
A Towson University–led study reveals wide geographic variation in caregiver-reported US clinician recommendations to adolescents regarding the human papillomavirus (HPV) vaccine.
For the study, published last week in Cancer Causes & Control, the researchers modeled data from the 2023 National Immunization Survey–Teen on state-level variations in clinician HPV-vaccination guidance for adolescents aged 13 to 17, with California as the reference state.
The HPV vaccine prevents viral infection that can cause different types of cancer, including cervical cancer.
“Adolescents aged 13–17 years represent a particularly important population for examining provider recommendations because they remain eligible for routine and catch-up HPV vaccination,” the authors wrote.“Understanding state-level variation may help identify local patterns that are masked by broader regional analyses and inform more targeted public health policies and interventions.”
Lack of doctor training, time constraints
HPV recommendations varied widely by state. For example, recommendations were less likely in Arkansas (adjusted odds ratio [aOR], 0.56), Georgia (aOR, 0.49), and Mississippi (aOR, 0.42), although the confidence intervals of all findings were wide, indicating imprecision.“This finding may, to some extent, explain the lower vaccination rates observed in these states, as health care provider recommendation is a strong driver of vaccine uptake,” the researchers wrote.The findings help determine which states contribute to the region’s overall low rates and pinpoints where additional public health efforts are most needed to improve the recommendation of HPV vaccine.
The odds of HPV recommendation delivery were higher in New Hampshire (aOR, 2.40). Wider variation was seen in the South than in the Northeast and Midwest. For instance, the rate of recommendation non-receipt was 16% in Maryland and 41% in Mississippi.
Some Northeastern and Western states had a higher likelihood of HPV-vaccine recommendation receipt (eg, only 12% of respondents in New Hampshire and 19% in Colorado reported not receiving a recommendation).
The lower rates of recommendation in the South may be partially attributed to barriers such as a lack of physician training, time constraints, and a paucity of effective tools and patient education materials, the researchers said.
“The findings help determine which states contribute to the region’s overall low rates and pinpoints where additional public health efforts are most needed to improve the recommendation of HPV vaccine,” they wrote.
CWD digest: Idaho, Wisconsin, Georgia report cases in previously unaffected areas
News briefToday at 3:40 p.m.
Mary Van Beusekom, MS
Topics
Chronic Wasting Disease
- Idaho: Yesterday, Idaho Fish and Game (IDFG) reported the first chronic wasting disease (CWD) identification in Hunting Unit 13, along the Snake River and the Oregon border, in a hunter-harvested mule deer buck. It is near a previous CWD detection in Unit 18. “Idaho Fish and Game has tested more than 3,500 deer and elk for CWD so far in 2026, and this is the first CWD detection outside of Units 1, 14, 15, 18, and 23 where deer and elk have previously tested positive,” IDFG said in a news release. Stacey Dauwalter, IDFG wildlife health program coordinator, said, “We encourage the public to continue supporting CWD surveillance by reporting road-killed deer and elk, animals found dead, and animals exhibiting unusual behavior.”
- Wisconsin: The detection of CWD in a wild, hunter-harvested buck in Pepin County, Wisconsin, has triggered the extension of the county’s feeding and baiting ban for another three years, the Wisconsin DNR announced yesterday in a news release. The case is the first for Pepin County, which is located in the far west-central part of the state on the Minnesota border. Existing baiting and feeding bans in bordering counties are unaffected by the finding. “Baiting or feeding deer encourages them to congregate unnaturally around a shared food source where infected deer can spread CWD through direct contact with healthy deer or indirectly by leaving behind infectious prions in their saliva, blood, feces and urine,” the DNR said.
- Georgia: CWD has been discovered for the first time in Coffee County, Georgia, resulting in the addition of Coffee and Cook counties to the state’s CWD Management Area (CMA). Coffee County is located in southern Georgia, in the Lower Coastal Plain and wiregrass region. Georgia documented its first-ever case in January 2025, the Georgia Department of Natural Resources (DNR) said late last week. The CMA now consists of Atkinson, Lanier, Berrien, Lowndes, Coffee, and Cook counties.
Quick takes: Cyclospora post-mortem, access to Ebola drug, changes to local health departments
News briefToday at 2:22 p.m.
Chris Dall, MA
Topics
Cyclospora
Ebola
Public Health
- Three US senators this week sent a letter to the inspector general of the Department of Health and Human Services requesting an investigation into this summer’s multistate Cyclospora outbreak. Specifically, the letter from senators Patty Murray (D-WA), Jeanne Shaheen (D-NH), and Tammy Baldwin (D-WI) asks Inspector General Marcia Bell to look into how personnel and policy changes at the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) contributed to the outbreak, which was linked to contaminated lettuce from Mexico. “It is clear that the FDA and CDC failed to adequately prevent and respond to this outbreak, and we believe that is, in no small part, due to this Administration’s illegal staffing cuts over the last 18 months,” the letter states. “Additionally, we are concerned that political interference resulted in delayed recalls and inspections of facilities linked to this outbreak.”
- Drugmaker Gilead Sciences announced yesterday that it has signed licensing agreements with three generic drug manufacturers to support potential future access to obeldesivir, an experimental antiviral being evaluated as post-exposure prophylaxis (prevention) for Bundibugyo Ebola in a phase 3 trial in the Democratic Republic of Congo. The agreements cover 127 low- and middle-income countries. “These agreements reflect our commitment to preparing for future access while clinical research is ongoing, so that we are better positioned to respond if these investigational medicines demonstrate benefit and gain regulatory approval,” Jaime McCoy, vice president of patient solutions at Gilead Sciences, said in a company press release.
- New data published yesterday by the National Association of County and City Health Officials show a mixed picture for local health departments around the country. Nearly one in five departments reported service expansions, with notable growth seen in substance abuse prevention (31%) and mental health (25%) services. But the share of departments reporting at least one job loss due to layoffs or attrition rose from 17% in 2022 to 24% in 2024, and nearly equal proportions of local health departments reported budget increases (28%) and budget decreases (27%) in 2025. The findings are based on responses from 2,493 local health departments.